Antineoplaston treatment for advanced hepatocellular carcinoma

Oncology Reports

Volumn 5, Issue 6, 1998, Pages 1363-1367

  Kumabe, Tsutomu ^a   Tsuda, Hideaki ^a   Uchida, Masafumi ^a   Ogoh, Yoshio ^a   Hayabuchi, Naofumi ^a   Sata, Michio ^a   Nakashima, Osamu ^a   Hara, Hiroshi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antineoplastone; Hepatocellular carcinoma; Maintenance therapy; Quality of life

Indexed keywords

3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CASE REPORT; CLINICAL TRIAL; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER BLOOD FLOW; LIVER CELL CARCINOMA; LIVER FAILURE; MALE; PORTAL VEIN; PRIORITY JOURNAL; TREATMENT INDICATION; TUMOR BLOOD FLOW;

EID: 0031667422     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.6.1363     Document Type: Article

References (10)

1. Burzynski SR: Antineoplastons: biochemical defense against cancer. Physiol Chem Phys 8: 275-279, 1976.
2. Burzynski SR: Biologically active peptides in human urine. Isolation of a group of medium sized peptides. Physiol Chem Phys 5: 437-447, 1973.
3. Burzynski SR, Loo TL, Ho DH, Georgiades PN and Kratenstein H: Biologically active peptides in human urine: III, Inhibitors of the growth of human leukemia, osteosarcoma and HeLa cells. Physiol Chem Phys 8: 13-22, 1976.
4. Burzynski SR and Hai TT: Antineoplaston A10. Drugs Future 10: 103-105, 1985.
5. Hendry MB, Muldoon TG, Burzynski SR, Copland JA and Lerner AF: Stereochemical modeling studies of the interaction of antineoplaston A10 with DNA. Drugs Exp Clin Res 1 (Suppl. 1): 77-82, 1986.
6. Eriguchi N, Hara H, Yoshida H, Nishida H and Nakayama T: Chemopreventive effect of antineoplaston A10 on urethane induced pulmonary neoplasma in mice. J Jpn Soc Cancer Ther 23: 1560-1565, 1988.
7. Burzynski SR: Potential of antineoplastons in disease of old age. Drugs Aging 7: 157-167, 1995.
8. Samid D, Yeh TJ and Shack S: Interferon in combination with antitumorigenic phenyl derivatives; potentiation of INF-α activity in vitro. Br J Haematol 79 (Suppl 1): 81-83, 1991.
9. Burzynski SR, Mohabbat MO and Lee SS: Preclinical studies of antineoplaston AS2-1 and antineoplaston AS2-5. Drugs Exp Clin Res (Suppl 1): 25-28, 1986.
10. Tsuda H, Hara H, Eriguchi N, Nishida H, Yoshida H, Kumabe T and Sugita Y: Toxicology study of antineoplaston A10 and AS2-1 in cancer patients. Kurume Med J 42: 241-249, 1995.